Laman Utama688235 • SHA
add
Beigene Ltd
Tutup sebelumnya
¥230.20
Julat hari
¥214.55 - ¥231.37
Julat tahun
¥111.22 - ¥248.00
Permodalan pasaran
185.35B CNY
Bilangan Purata
2.32J
Nisbah P/E
-
Hasil dividen
-
Pertukaran utama
SHA
Dalam berita
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (USD) | Dis 2024info | Perubahan T/T |
|---|---|---|
Hasil | 1.19B | 84.84% |
Perbelanjaan pengendalian | 1.09B | 19.51% |
Pendapatan bersih | -139.70J | 58.27% |
Margin untung bersih | -11.75 | 77.43% |
Pendapatan bagi setiap syer | -0.80 | -196.59% |
EBITDA | -33.25J | 90.73% |
Kadar cukai berkesan | -112.84% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (USD) | Dis 2024info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 2.63B | -17.16% |
Jumlah aset | 5.92B | 1.99% |
Jumlah liabiliti | 2.59B | 14.14% |
Jumlah ekuiti | 3.33B | — |
Syer tertunggak | 106.72J | — |
Harga kepada buku | 7.37 | — |
Pulangan pada aset | -3.26% | — |
Pulangan pada modal | -4.29% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (USD) | Dis 2024info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | -139.70J | 58.27% |
Tunai daripada operasi | 111.61J | 128.21% |
Tunai daripada pelaburan | -247.31J | 26.86% |
Tunai daripada pembiayaan | 30.05J | -92.11% |
Perubahan bersih dalam tunai | -155.64J | 57.59% |
Aliran tunai bebas | 434.97J | 505.95% |
Perihal
BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment. Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has offices in North America, Europe, South America, Asia and Australia. BeiGene has a large presence in the Chinese market. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November, 2024 the company announced its intention to rebrand as BeOne Medicines. Wikipedia
Diasaskan
28 Okt 2010
Tapak web
Pekerja
11,000
